WO2004005310A3 - New compounds, compositions and methods for treatment of inflammatory diseases and conditions - Google Patents

New compounds, compositions and methods for treatment of inflammatory diseases and conditions Download PDF

Info

Publication number
WO2004005310A3
WO2004005310A3 PCT/HR2003/000037 HR0300037W WO2004005310A3 WO 2004005310 A3 WO2004005310 A3 WO 2004005310A3 HR 0300037 W HR0300037 W HR 0300037W WO 2004005310 A3 WO2004005310 A3 WO 2004005310A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory
macrolide
steroid
treatment
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HR2003/000037
Other languages
French (fr)
Other versions
WO2004005310A2 (en
Inventor
Mladen Mercep
Milan Mesic
Linda Tomaskovic
Stribor Markovic
Oresta Makaruha
Visnja Poljak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliva Farmaceutika dd
Original Assignee
Pliva Farmaceutika dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP03762825A priority Critical patent/EP1521764A2/en
Priority to HR20050004A priority patent/HRP20050004A2/en
Priority to NZ537717A priority patent/NZ537717A/en
Priority to JP2004519021A priority patent/JP4790263B2/en
Priority to YUP-2005/0008A priority patent/RS20050008A/en
Priority to HK06102989.3A priority patent/HK1082256B/en
Priority to BR0312634-0A priority patent/BR0312634A/en
Priority to AU2003255851A priority patent/AU2003255851B2/en
Priority to CA002489402A priority patent/CA2489402A1/en
Application filed by Pliva Farmaceutika dd filed Critical Pliva Farmaceutika dd
Publication of WO2004005310A2 publication Critical patent/WO2004005310A2/en
Publication of WO2004005310A3 publication Critical patent/WO2004005310A3/en
Priority to IL165657A priority patent/IL165657A/en
Anticipated expiration legal-status Critical
Priority to NO20050570A priority patent/NO329885B1/en
Priority to IS7684A priority patent/IS7684A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention relates (a) to new compounds represented by Formula (I): wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, S represents a steroid subunit (steroid moiety) derived from steroid drug with anti-inflammatory activity and L represents a linker molecule linking M and S, (b) to their pharmacologically acceptable salts, prodrugs and solvates, (c) to processes and intermediates for their preparation, and (d) to their use in the treatment of inflammatory diseases and conditions in humans and animals. Such compounds inhibit many cytokines and immune mediators involved in immune responses which cause inflammation, allergy, or alloimmunity, including without limitation IL-1, 2, 4, 5, 6, 10, 12, GMCSF, ICAM, and TNF-α. Importantly, anti-inflammatory steroids exert a direct anti-inflammatory effect through binding to the glucocorticosteroid receptor.
PCT/HR2003/000037 2002-07-08 2003-07-08 New compounds, compositions and methods for treatment of inflammatory diseases and conditions Ceased WO2004005310A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA002489402A CA2489402A1 (en) 2002-07-08 2003-07-08 New compounds, compositions and methods for treatment of inflammatory diseases and conditions
NZ537717A NZ537717A (en) 2002-07-08 2003-07-08 New compounds, compositions and methods for treatment of inflammatory diseases and conditions
JP2004519021A JP4790263B2 (en) 2002-07-08 2003-07-08 Novel compounds, compositions and methods for treating inflammatory diseases and conditions
YUP-2005/0008A RS20050008A (en) 2002-07-08 2003-07-08 New compounds,compositions and methods for treatment of inflammatory diseases and conditions
HK06102989.3A HK1082256B (en) 2002-07-08 2003-07-08 New compounds, compositions and methods for treatment of inflammatory diseases and conditions
BR0312634-0A BR0312634A (en) 2002-07-08 2003-07-08 New compounds, compositions and methods for treating inflammatory diseases and conditions
AU2003255851A AU2003255851B2 (en) 2002-07-08 2003-07-08 New compounds, compositions and methods for treatment of inflammatory diseases and conditions
EP03762825A EP1521764A2 (en) 2002-07-08 2003-07-08 New compounds, compositions and methods for treatment of inflammatory diseases and conditions
HR20050004A HRP20050004A2 (en) 2002-07-08 2003-07-08 New compounds, compositions and methods for treatment of inflammatory diseases and conditions
IL165657A IL165657A (en) 2002-07-08 2004-12-08 Compounds, process for their preparation, compositions comprising them and use thereof for the manufacture of medicaments for treating inflammatory diseases and conditions
NO20050570A NO329885B1 (en) 2002-07-08 2005-02-02 New compounds, process for their preparation, use of the compounds and pharmaceutical composition comprising such a compound
IS7684A IS7684A (en) 2002-07-08 2005-02-03 New compounds, preparations and methods for the treatment of inflammatory diseases and conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39467002P 2002-07-08 2002-07-08
US60/394,670 2002-07-08

Publications (2)

Publication Number Publication Date
WO2004005310A2 WO2004005310A2 (en) 2004-01-15
WO2004005310A3 true WO2004005310A3 (en) 2004-04-22

Family

ID=30115752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HR2003/000037 Ceased WO2004005310A2 (en) 2002-07-08 2003-07-08 New compounds, compositions and methods for treatment of inflammatory diseases and conditions

Country Status (15)

Country Link
US (1) US7091187B2 (en)
EP (1) EP1521764A2 (en)
JP (1) JP4790263B2 (en)
CN (1) CN100577681C (en)
AR (1) AR040484A1 (en)
AU (1) AU2003255851B2 (en)
BR (1) BR0312634A (en)
CA (1) CA2489402A1 (en)
IS (1) IS7684A (en)
NO (1) NO329885B1 (en)
NZ (1) NZ537717A (en)
PL (1) PL374731A1 (en)
RS (1) RS20050008A (en)
RU (1) RU2330858C2 (en)
WO (1) WO2004005310A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070174A2 (en) * 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AR043050A1 (en) * 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc BIFunctional HETEROCICLICAL COMPOUNDS AND METHODS TO PREPARE AND USE THE SAME
BRPI0408117A (en) * 2003-03-05 2006-03-01 Rib X Pharmaceuticals Inc bifunctional heterocyclic compounds and methods of production and use thereof
HRP20030324A2 (en) * 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect
WO2005042554A1 (en) * 2003-10-30 2005-05-12 Rib-X Pharmaceuticals, Inc. Bifunctional macrolide heterocyclic compounds and methods of making and using the same
JP2007512256A (en) * 2003-11-18 2007-05-17 リブ−エックス ファーマシューティカルズ，インコーポレイテッド Bifunctional macrolide heterocyclic compounds, methods of producing them and methods of using them
EP2716647A3 (en) 2004-02-27 2014-08-20 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
RU2007108544A (en) * 2004-08-12 2008-09-20 Глаксосмитклайн Истраживацки Центар Загреб Д.О.О.(Hr) APPLICATION OF CELL-SPECIFIC CONJUGATES FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT
US20060183696A1 (en) * 2004-08-12 2006-08-17 Pliva-Istrazivacki Institut D.O.O. Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract
US20090048221A1 (en) * 2004-10-27 2009-02-19 Mladen Mercep Conjugates with Anti-Inflammatory Activity
KR20070105993A (en) * 2005-01-13 2007-10-31 글락소스미쓰클라인 이스트라지바치키 센타 자그레브 디.오.오. Macrolides with anti-inflammatory activity
JP2008526945A (en) * 2005-01-14 2008-07-24 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 9A-carbamoyl and thiocarbamoyl azalide having anti-inflammatory activity
CA2615581A1 (en) * 2005-07-26 2007-02-01 Merckle Gmbh Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase
EP3406263A1 (en) 2007-05-29 2018-11-28 Novartis AG New indications for anti-il-1beta therapy
WO2009006403A2 (en) * 2007-06-29 2009-01-08 Georgia Tech Research Corporation Non-peptide macrocyclic histone deacetylase (hdac) inhibitors and methods of making and using thereof
US8871728B2 (en) 2007-06-29 2014-10-28 Georgia Tech Research Corporation Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof
CA2703475A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US8796232B2 (en) 2008-10-24 2014-08-05 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
CN102378763A (en) 2009-01-30 2012-03-14 葛兰素集团有限公司 Anti-inflammatory macrolide
US9937194B1 (en) * 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
JP5914335B2 (en) 2009-09-10 2016-05-11 センプラ ファーマシューティカルズ，インコーポレイテッド Method for treating malaria, tuberculosis and MAC disease
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
JP6042334B2 (en) 2010-09-10 2016-12-14 センプラ ファーマシューティカルズ，インコーポレイテッド Hydrogen bond forming fluoroketolides for disease treatment
CN104470527B (en) 2012-03-27 2019-05-28 森普拉制药公司 Parenteral formulations for administration of macrolide antibiotics
US20140256032A1 (en) * 2013-03-08 2014-09-11 Church & Dwight Co., Inc. Light scattering sperm assesment device and method
RU2015138796A (en) 2013-03-14 2017-04-19 Семпра Фармасьютикалс, Инк. METHODS AND COMPOSITIONS FOR TREATMENT OF RESPIRATORY DISEASES
WO2014145210A1 (en) 2013-03-15 2014-09-18 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
CN103641869B (en) * 2013-12-30 2016-04-06 广州自远生物科技有限公司 A kind of synthetic method of Tulathromycin
WO2016209943A1 (en) * 2015-06-22 2016-12-29 The Brigham And Women's Hospital, Inc Home evaluation of the quality of semen samples
GB201520419D0 (en) 2015-11-19 2016-01-06 Epi Endo Pharmaceuticals Ehf Compounds
GB201608236D0 (en) 2016-05-11 2016-06-22 Fidelta D O O Seco macrolide compounds
EP3612543B1 (en) * 2017-04-20 2022-11-23 Rising Tide Foundation Azithromycin derivatives containing a phosphonium ion as anticancer agents
US11427606B2 (en) * 2017-04-20 2022-08-30 Rising Tide Foundation Azithromycin derivatives containing a phosphonium ion as anticancer agents
GB202404587D0 (en) 2024-03-28 2024-05-15 Epiendo Pharmaceuticals Ehf Chemical forms

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283055A2 (en) * 1987-09-03 1988-09-21 SOUR PLIVA farmaceutska, Kemijska prehrambena i kozmeticka industrija, n.sol.o. 10-Dihydro-10-deoxo-11-azaerythronolide-A-compounds, methods and intermediates for the manufacture thereof and their use in pharmaceuticals and in the manufacture thereof
WO1997041255A1 (en) * 1996-04-26 1997-11-06 Massachusetts Institute Of Technology Three-hybrid screening assay
WO1999064040A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel polyene macrolide compounds and uses
WO2000064882A2 (en) * 1999-04-23 2000-11-02 Glaxo Group Limited Enantiomers of mercapto lactones and processes for their synthesis
WO2002055531A1 (en) * 2001-01-09 2002-07-18 Pliva D.D. Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
ES2032831T5 (en) * 1986-08-19 2001-02-16 Genentech Inc DEVICE AND DISPERSION FOR INTRAPULMONARY SUPPLY OF POLYPEPTIDE AND CYTOKIN GROWTH FACTORS.
LU87036A1 (en) * 1987-11-04 1989-06-14 Oreal UNSATURATED CYCLOALIPHATIC ESTERS OF MACROLIDIC AND LINCOSAMIDIC ANTIBIOTICS, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM
SE9100342D0 (en) 1991-02-04 1991-02-04 Astra Ab NOVEL STEROID ESTERS
SE9100341D0 (en) 1991-02-04 1991-02-04 Astra Ab NOVEL STEROIDS
GB9225923D0 (en) 1992-12-11 1993-02-03 Rhone Poulenc Rorer Ltd New compositions of matter
EP0675897B1 (en) 1992-12-24 1997-06-18 Rhone-Poulenc Rorer Limited New steroids
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
FR2719587B1 (en) 1994-05-03 1996-07-12 Roussel Uclaf New erythromycin derivatives, their preparation process and their use as drugs.
KR970704455A (en) 1994-08-12 1997-09-06 우에하라 아끼라 Interleukin 5 Production Inhibitor
WO1996004920A1 (en) 1994-08-12 1996-02-22 Taisho Pharmaceutical Co., Ltd. Interleukin-5 production inhibitor
FR2742757B1 (en) * 1995-12-22 1998-01-30 Roussel Uclaf NOVEL ERYTHROMYCIN DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
DE19616573C2 (en) * 1996-04-25 1999-03-04 Pari Gmbh Use of subcritical blowing agent mixtures and aerosols for the micronization of drugs with the help of dense gases
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
HN1998000074A (en) 1997-06-11 1999-01-08 Pfizer Prod Inc DERIVATIVES FROM MACROLIDES C-4 SUBSTITUTED
GB2327084A (en) 1997-07-08 1999-01-13 Merck & Co Inc 9a-Aza-3-ketolide antibiotics
EP0895999A1 (en) 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
JP3530004B2 (en) * 1998-02-06 2004-05-24 株式会社日立ユニシアオートモティブ Inhalation type dispenser
HRP980189B1 (en) 1998-04-06 2004-04-30 Pliva Pharm & Chem Works Novel 15-membered lactams ketolides
US6043227A (en) 1998-08-19 2000-03-28 Pfizer Inc. C11 carbamates of macrolide antibacterials
US6297260B1 (en) * 1998-10-30 2001-10-02 Nitromed, Inc. Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
IT1306205B1 (en) 1999-01-15 2001-05-30 Zambon Spa MACROLIDS WITH ANTI-INFLAMMATORY ACTIVITY.
EP1483579A4 (en) 2002-02-15 2006-07-12 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THE PREPARATION AND USE OF CONJUGATES, FORMULATION AND PHARMACEUTICAL APPLICATIONS OBTAINED FROM SUCH CONJUGATES
US20040186063A1 (en) * 2002-02-15 2004-09-23 Hans-Jurgen Gutke Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2003070254A1 (en) 2002-02-15 2003-08-28 Sympore Gmbh Antibiotic conjugates
WO2003070174A2 (en) 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283055A2 (en) * 1987-09-03 1988-09-21 SOUR PLIVA farmaceutska, Kemijska prehrambena i kozmeticka industrija, n.sol.o. 10-Dihydro-10-deoxo-11-azaerythronolide-A-compounds, methods and intermediates for the manufacture thereof and their use in pharmaceuticals and in the manufacture thereof
WO1997041255A1 (en) * 1996-04-26 1997-11-06 Massachusetts Institute Of Technology Three-hybrid screening assay
WO1999064040A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel polyene macrolide compounds and uses
WO2000064882A2 (en) * 1999-04-23 2000-11-02 Glaxo Group Limited Enantiomers of mercapto lactones and processes for their synthesis
WO2002055531A1 (en) * 2001-01-09 2002-07-18 Pliva D.D. Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRANDT-RAUF P ET AL: "FLUORESCENT ASSAY FOR ESTIMATING THE BINDING OF ERYTHROMYCIN DERIVATIVES TO RIBOSOMES", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 14, no. 1, July 1978 (1978-07-01), pages 88 - 94, XP000923144, ISSN: 0066-4804 *
ROMO D ET AL: "Total Synthesis and Immunosuppressive Activity of (-)-Pateamine A and Related Compounds: Implementation of beta-Lactam Based MacroCYCLIZATION", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 120, no. 47, 1998, pages 12237 - 12254, XP002200620, ISSN: 0002-7863 *
See also references of EP1521764A2 *

Also Published As

Publication number Publication date
WO2004005310A2 (en) 2004-01-15
IS7684A (en) 2005-02-03
RU2005103226A (en) 2005-11-20
AR040484A1 (en) 2005-04-06
RS20050008A (en) 2007-06-04
AU2003255851B2 (en) 2009-07-23
HK1082256A1 (en) 2006-06-02
US20040014685A1 (en) 2004-01-22
CN1692123A (en) 2005-11-02
RU2330858C2 (en) 2008-08-10
BR0312634A (en) 2005-05-10
US7091187B2 (en) 2006-08-15
NO20050570L (en) 2005-03-04
NO329885B1 (en) 2011-01-17
JP2005535654A (en) 2005-11-24
PL374731A1 (en) 2005-10-31
EP1521764A2 (en) 2005-04-13
JP4790263B2 (en) 2011-10-12
AU2003255851A1 (en) 2004-01-23
CN100577681C (en) 2010-01-06
NZ537717A (en) 2006-04-28
CA2489402A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
BR0312634A (en) New compounds, compositions and methods for treating inflammatory diseases and conditions
WO2004005309A3 (en) Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
CY1110866T1 (en) MACROLIDES WITH ANTI-INFLAMMATIVE ACTIVITY
HRP20050002A2 (en) Novel compounds, compositions as carriers for steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules
MX2010005861A (en) Novel glucocorticoid receptor agonists.
WO2007002701A3 (en) Anti-inflammatory aryl nitrile compounds
EP2319535A3 (en) Pharmaceutical composition for treatment of diseases caused by IL-6 production
BRPI0410490A (en) macrolide compound, pharmaceutical composition and method of treatment comprising the same
PT912185E (en) NEW PHARMACEUTICAL FORMULATIONS CONTAINING ESTER NITRATE DERIVATIVES FROM PROVIDED ESTEROIDS AS ANTI-INFLAMMATORY DRUGS
NZ516506A (en) Interleukin-5 inhibiting 6-azauracil derivatives
DE60103140D1 (en) PROPANCARBONIC ACID-AMIDOXIME DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS THAT HAVE RECEIVED THEM
WO2007025632A3 (en) Nitrooxy derivatives op glucocorticoids
FR2872165B1 (en) NEW PYRIMIDO-BENZIMIDAZOLE DERIVATIVES
MX2007005073A (en) Conjugates with anti-inflammatory activity.
WO2007022305A3 (en) 2-aminoimidazopyridines for treating neurodegenerative diseases
DE60318320D1 (en) BENZIMIDAZOLONE AND ITS USE AS CYTOKININ HIBITORS
DE60317214D1 (en) CRYSTALLINE GAMMA LACTON DER17BETA HYDROXY-7ALPHA- (5'-METHYL-2'-FURYL) -PREGNA-4,9 (11) -DI-3-ONE-21-CARBOXYLIC ACID
WO2003039482A3 (en) Polymorphs of fexofenadine base
CY1110192T1 (en) Crystalline forms of macrolide compounds with anti-inflammatory action
Dalakas Update on the molecular pathogenesis of inflammatory myopathies
DE602006011515D1 (en) AMIDIN DERIVATIVES OF 2-HETEROARYL CHINAZOLINES AND CHINOLINES; EFFECTIVE ANALGETICS AND ANTI-INFLAMMATORY AGENTS
WO2004106935A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103)
WO2004082572A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 87 (gpr87)
TH80753A (en) Glucuronides, metabolites and epimers involved in such substances of Taikicyclin
UA95861C2 (en) Glucocorticoid receptor agonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0008

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2489402

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: P20050004A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 2004519021

Country of ref document: JP

Ref document number: 2003255851

Country of ref document: AU

Ref document number: 20038160935

Country of ref document: CN

Ref document number: 374731

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2003762825

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 537717

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 399/DELNP/2005

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005103226

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2003762825

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 537717

Country of ref document: NZ